NVO ▲ +3.3% - Novo Nordisk A/S $NVO NOVO NORDISK CEO SAYS THE WEGOVY PILL IS STILL CAPTURING AROUND 80% OF NEW ORAL PATIENT STARTS; IMPROVEMENTS IN THE OUTLOOK IS MAINLY DRIVEN BY INCREASED EXPECTATIONS FOR GLP-1 PRODUCT SALES 04-NOV-2026 05:24 AM ET